[go: up one dir, main page]

MX2010003200A - Composiciones de imatibnib estables. - Google Patents

Composiciones de imatibnib estables.

Info

Publication number
MX2010003200A
MX2010003200A MX2010003200A MX2010003200A MX2010003200A MX 2010003200 A MX2010003200 A MX 2010003200A MX 2010003200 A MX2010003200 A MX 2010003200A MX 2010003200 A MX2010003200 A MX 2010003200A MX 2010003200 A MX2010003200 A MX 2010003200A
Authority
MX
Mexico
Prior art keywords
stable
compositions
imatinib compositions
stable imatinib
imatinib
Prior art date
Application number
MX2010003200A
Other languages
English (en)
Inventor
Zvika Doani
Bella Gerber
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2010003200A publication Critical patent/MX2010003200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se revelan formulaciones que contienen imatinib, preferentemente mesilato de imatinib, con alta estabilidad polim?rfica y los procesos para la preparaci?n de ellos.
MX2010003200A 2007-09-25 2008-09-25 Composiciones de imatibnib estables. MX2010003200A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99532107P 2007-09-25 2007-09-25
US99565107P 2007-09-26 2007-09-26
PCT/US2008/077750 WO2009042809A1 (en) 2007-09-25 2008-09-25 Stable imatinib compositions

Publications (1)

Publication Number Publication Date
MX2010003200A true MX2010003200A (es) 2010-04-30

Family

ID=40070888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003200A MX2010003200A (es) 2007-09-25 2008-09-25 Composiciones de imatibnib estables.

Country Status (9)

Country Link
US (2) US20090087489A1 (es)
EP (2) EP2081556A1 (es)
JP (2) JP2010540465A (es)
KR (1) KR101041203B1 (es)
BR (1) BRPI0817946A2 (es)
CA (1) CA2700844A1 (es)
MX (1) MX2010003200A (es)
RU (1) RU2470641C2 (es)
WO (2) WO2009042803A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160798A1 (en) * 2010-06-21 2011-12-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
CN102552268A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种含有α晶型甲磺酸伊马替尼的药物制剂
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
EA017781B1 (ru) * 2011-05-24 2013-03-29 Тева Канада Лимитед Покрытая пленочной оболочкой таблетка, содержащая иматиниб мезилат, и способ ее получения
CA2856692C (en) 2011-11-24 2016-06-28 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Imatinib solid dosage forms reconstituted just before use
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
KR101520792B1 (ko) * 2013-04-10 2015-05-15 보령제약 주식회사 고부하 이매티닙 정제
EP2803353B1 (en) * 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
AU2014288866B2 (en) * 2013-07-09 2017-07-13 Shilpa Medicare Limited Oral pharmaceutical compositions comprising Imatinib mesylate
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
WO2019016673A2 (en) * 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
US20220175774A1 (en) * 2020-12-07 2022-06-09 Alembic Pharmaceuticals Limited Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP4086945B2 (ja) * 1996-12-10 2008-05-14 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 非毒性Ｖ．Ｃｈｏｌｅｒａｅ株の単離法およびその株由来のコレラワクチンの製造法
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP2005526095A (ja) * 2002-03-20 2005-09-02 エラン ファーマ インターナショナル，リミティド 脆砕性の低い急速溶解投与剤型
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004010981A1 (en) 2002-07-29 2004-02-05 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
WO2004024895A2 (en) * 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
WO2004108067A2 (en) 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
TR200504337T1 (tr) 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
WO2004108699A1 (en) 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
WO2005051350A2 (en) 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
EP1720853B2 (en) * 2004-02-11 2023-06-28 Natco Pharma Limited Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
US20060034927A1 (en) * 2004-08-04 2006-02-16 Gemma Casadevall Means of delivering drugs in an ascending zero order release pattern
EP1786781A2 (en) 2004-08-27 2007-05-23 GPC Biotech AG Pyrimidine derivatives
KR101348625B1 (ko) * 2004-09-02 2014-01-07 씨아이피엘에이 엘티디. 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
AU2006255177A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
DE502006005084D1 (de) * 2005-08-15 2009-11-26 Siegfried Generics Int Ag Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
AR055613A1 (es) 2005-08-26 2007-08-29 Novartis Ag Formas cristalinas delta y epsilon de mesilato de imatinib
WO2007059963A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate
BRPI0602338A (pt) 2006-03-24 2007-12-11 Univ Kyushu Nat Univ Corp compostos orgánicos
KR101019451B1 (ko) * 2006-04-27 2011-03-07 아이박스 파마슈티컬스 에스.알.오. 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
MX2008008447A (es) * 2006-10-26 2008-09-15 Sicor Inc Proceso para la preparacion de imatinib.
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
DK2305263T3 (da) * 2007-06-07 2012-10-22 Novartis Ag Stabiliserede amorfe former af imatinibmesylat

Also Published As

Publication number Publication date
RU2470641C2 (ru) 2012-12-27
WO2009042803A1 (en) 2009-04-02
US8414918B2 (en) 2013-04-09
WO2009042809A8 (en) 2009-07-02
EP2086520A1 (en) 2009-08-12
EP2081556A1 (en) 2009-07-29
US20090087489A1 (en) 2009-04-02
BRPI0817946A2 (pt) 2015-05-05
KR20100054843A (ko) 2010-05-25
CA2700844A1 (en) 2009-04-02
WO2009042809A1 (en) 2009-04-02
RU2010110982A (ru) 2011-09-27
JP2010540465A (ja) 2010-12-24
US20090092669A1 (en) 2009-04-09
JP2011140508A (ja) 2011-07-21
KR101041203B1 (ko) 2011-06-13

Similar Documents

Publication Publication Date Title
MX2010003200A (es) Composiciones de imatibnib estables.
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
IL200746A0 (en) Cyclopamine analog compounds, compositions comprising the same and uses thereof
UA97502C2 (ru) Кристаллическая твердая основа разагилина
IL204621A0 (en) Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
IL241634B (en) History of new benzodiazepines, preparations containing them and their uses
EP2227491A4 (en) POLYMER COMPOSITIONS ON ETHYLENE BASE, PROCESS FOR THEIR PRODUCTION AND ARTICLES THEREOF
MX2010007601A (es) Formulaciones de rasagilina, su preparacion y uso.
MX2009002241A (es) Compuestos adecuados para usarse en tintas y tintas que tienen esos compuestos.
IL200684A0 (en) Heterocyclic cyclopamine analog compounds, compositions comprising the same and uses thereof
MX2010004576A (es) Derivados de pirimidina novedosos.
IL181618A0 (en) Pharmaceutical solid-in-oil compositions for external administraton, methods for preparation and uses thereof
IL212836A0 (en) Azaquinolinone derivatives, compositions comprising the same and uses thereof
IL210722A0 (en) Benzazepine derivatives, compositions comprising the same and uses thereof
GEP20156230B (en) Forms of rifaximin and usage thereof
WO2008057291A3 (en) Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
IL185353A0 (en) Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
IL184890A0 (en) Adipose-derived adult stromal cell, methods for generating the same and compositions containing the same
TW200800967A (en) Benzimidazole thiophene compounds
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
EP2282735A4 (en) COMPOUNDS, COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
MX2010002028A (es) Metodos y composiciones para modular celulas t.
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2008027600A3 (en) Imatinib compositions